Literature DB >> 23296469

Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients.

Silvia Nardelli1, Ilaria Pentassuglio, Chiara Pasquale, Lorenzo Ridola, Federica Moscucci, Manuela Merli, Concetta Mina, Massimo Marianetti, Mariangela Fratino, Chiara Izzo, Carlo Merkel, Oliviero Riggio.   

Abstract

HRQoL is impaired in cirrhosis. Establishing the relevance of depression, anxiety, alexithymia and cirrhosis stage on the patients' HRQoL. Sixty cirrhotics underwent a neuropsychological assessment, including ZUNG-SDS, STAI Y1-Y2 and TAS-20. Minimal hepatic encephalopathy (MHE) was detected by PHES, HRQoL by Short-Form-36 (SF-36). Depression was detected in 34 patients (57 %, 95%CI = 44-70 %), state-anxiety in 16 (27 %, 95%CI = 15-38 %), trait-anxiety in 17 (28 %, 95%CI = 17-40 %), alexithymia in 14 (31 % 95%CI = 16-46 %) and MHE in 22 (37 %, 95%CI = 24-49 %). Neuropsychological symptoms were unrelated to cirrhosis stage, hepatocellular carcinoma or MHE. A significant correlation was observed among psychological test scores and summary components of SF-36. At multiple linear regression analysis including Child-Pugh and MELD scores, previous-HE and the psychological test scores as possible covariates, alexithymia and depression as well as to the Child-Pugh score were significantly related to the SF-36 mental component; while trait-anxiety was the only variable significantly and independently related to the SF-36 physical component. Depression, state and trait-anxiety and alexithymia symptoms are frequent in cirrhotics and are among the major determinants of the altered HRQoL.

Entities:  

Mesh:

Year:  2013        PMID: 23296469     DOI: 10.1007/s11011-012-9364-0

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  23 in total

Review 1.  Neuropsychological characterization of hepatic encephalopathy.

Authors:  K Weissenborn; J C Ennen; H Schomerus; N Rückert; H Hecker
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

2.  Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study.

Authors:  Piero Amodio; Francesca Campagna; Stefania Olianas; Pamela Iannizzi; Daniela Mapelli; Marco Penzo; Paolo Angeli; Angelo Gatta
Journal:  J Hepatol       Date:  2008-06-02       Impact factor: 25.083

3.  Quality of life in cirrhosis is related to potentially treatable factors.

Authors:  Iñigo Les; Eduardo Doval; Montserrat Flavià; Carlos Jacas; Guillermo Cárdenas; Rafael Esteban; Jaime Guardia; Juan Córdoba
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-02       Impact factor: 2.566

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  Factors associated with poor health-related quality of life of patients with cirrhosis.

Authors:  G Marchesini; G Bianchi; P Amodio; F Salerno; M Merli; C Panella; C Loguercio; G Apolone; M Niero; R Abbiati
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

6.  Self-rating depression scale in an outpatient clinic. Further validation of the SDS.

Authors:  W W Zung; C B Richards; M J Short
Journal:  Arch Gen Psychiatry       Date:  1965-12

7.  Orbitofrontal volume reductions during emotion recognition in patients with major depression.

Authors:  Johanna Scheuerecker; Eva M Meisenzahl; Nikolaos Koutsouleris; Martin Roesner; Veronika Schöpf; Jennifer Linn; Martin Wiesmann; Hartmut Brückmann; Hans-Jürgen Möller; Thomas Frodl
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

8.  Somatic/affective symptoms, but not cognitive/affective symptoms, of depression after acute coronary syndrome are associated with 12-month all-cause mortality.

Authors:  Annelieke M Roest; Brett D Thombs; Sherry L Grace; Donna E Stewart; Susan E Abbey; Peter de Jonge
Journal:  J Affect Disord       Date:  2010-12-14       Impact factor: 4.839

9.  Association between pretransplant psychological assessments and posttransplant psychiatric disorders in living-related transplantation.

Authors:  Isao Fukunishi; Yasutoshi Sugawara; Tadatoshi Takayama; Masatoshi Makuuchi; Hideo Kawarasaki; Owen S Surman
Journal:  Psychosomatics       Date:  2002 Jan-Feb       Impact factor: 2.386

10.  Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models.

Authors:  Paola Rocca; Elena Cocuzza; Roberta Rasetti; Giuseppe Rocca; Enrico Zanalda; Filippo Bogetto
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

View more
  29 in total

Review 1.  Diagnosis of minimal hepatic encephalopathy.

Authors:  Karin Weissenborn
Journal:  J Clin Exp Hepatol       Date:  2014-07-31

Review 2.  Minimal hepatic encephalopathy impairs quality of life.

Authors:  Swastik Agrawal; Sridharan Umapathy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-04

3.  Complementary and Alternative Medicine Use in United States Adults With Liver Disease.

Authors:  Jacqueline B Henson; Cristal L Brown; Shein-Chung Chow; Andrew J Muir
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

Review 4.  Palliative care for patients with end-stage liver disease.

Authors:  Anne M Larson
Journal:  Curr Gastroenterol Rep       Date:  2015-05

5.  Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score.

Authors:  Ankit V Patel; James B Wade; Leroy R Thacker; Richard K Sterling; Muhammad S Siddiqui; R Todd Stravitz; Arun J Sanyal; Velimir Luketic; Puneet Puri; Michael Fuchs; Scott Matherly; Melanie B White; Ariel Unser; Douglas M Heuman; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-28       Impact factor: 11.382

6.  Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Francesco Margari; Madia Lozupone; Francesco Minerva; Carla Di Gennaro; Orlando Todarello; Giuseppe Palasciano
Journal:  Clin Exp Med       Date:  2013-12-10       Impact factor: 3.984

7.  Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy.

Authors:  Madia Lozupone; Rodolfo Sardone; Rossella Donghia; Francesca D'Urso; Carla Piccininni; Petronilla Battista; Ilaria Di Gioia; Emanuela Resta; Fabio Castellana; Luisa Lampignano; Roberta Zupo; Ilaria Bortone; Vito Guerra; Chiara Griseta; Davide Seripa; Vincenzo Solfrizzi; Gianluigi Giannelli; Nicola Quaranta; Giancarlo Logroscino; Antonello Bellomo; Francesco Panza
Journal:  Geroscience       Date:  2020-10-31       Impact factor: 7.713

8.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

9.  Anxiety and depressive disorders among patients with esophageal cancer in Taiwan: a nationwide population-based study.

Authors:  Li-Yu Hu; Fan-Chen Ku; Yen-Po Wang; Cheng-Che Shen; Yu-Wen Hu; Chiu-Mei Yeh; Pan-Ming Chen; Huey-Ling Chiang; Ti Lu; Tzeng-Ji Chen; Chung-Jen Teng; Chia-Jen Liu
Journal:  Support Care Cancer       Date:  2014-09-02       Impact factor: 3.603

Review 10.  Qualifying and quantifying minimal hepatic encephalopathy.

Authors:  Marsha Y Morgan; Piero Amodio; Nicola A Cook; Clive D Jackson; Gerald Kircheis; Mette M Lauridsen; Sara Montagnese; Sami Schiff; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2015-09-28       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.